Novel piperazine and homopiperazine derivatives are agonists of melanocortin
receptor(s) and are useful for the treatment, control, or prevention of diseases
and disorders responsive to the activation of the melanocortin receptors. The compounds
of the present invention are therefore useful for treatment or prevention of diseases
and disorders such as obesity, diabetes, and sexual dysfunction.
